Results 1 to 10 of about 6,004 (159)
Inflammatory myopathy and severe rhabdomyolysis induced by leuprolide acetate therapy for prostate cancer: a case report [PDF]
Journal of Medical Case Reports, 2011 Introduction Leuprolide acetate is a synthetic analog of gonadotropin-releasing hormone used for the treatment of prostate cancer. Its side effects are hot flashes, nausea, and fatigue.
Rohacek Martin +2 more
doaj +4 more sources
Overdiagnosis of a typical carcinoid tumor as an adenocarcinoma of the lung: a case report and review of the literature [PDF]
World Journal of Surgical Oncology, 2012 Background Overdiagnosis of bronchopulmonary carcinoid tumors together with overtreatment can cause serious postoperative consequences for the patient.
Demirci Ilhan +5 more
doaj +3 more sources
Molecules, 2022 Leuprolide is a synthetic nonapeptide drug (pyroGlu-His-Trp-Ser-Tyr-d-Leu-Leu-Arg-Pro-NHEt) that acts as a gonadotropin-releasing hormone agonist. The continuous administration of therapeutic doses of leuprolide inhibits gonadotropin secretion, which is ...
Gi-Sang Seong +6 more
doaj +1 more source
Impact of Androgen Deprivation Therapy on Cardiovascular Outcomes in Prostate Cancer
Société Internationale d’Urologie Journal, 2022 PurposeSubstantial evidence indicates that men with prostate cancer are at an increased risk for cardiovascular disease, and medical and surgical androgen deprivation therapy is associated with further increased cardiovascular risk. There are conflicting
Laurence Klotz +3 more
doaj +1 more source
Majalah Obstetri dan Ginekologi, 2022 HIGHLIGHTS 1. Endometriosis treatment remains controversial, whether it should be managed with hormonal modulation and/or surgical removal of the lesion. 2.
Raudatul Hikmah +2 more
doaj +1 more source
Clinical development of the GnRH agonist leuprolide acetate depot
F&S Reports, 2023 Leuprolide acetate is the first GnRH agonist that entered clinical development after the discovery of the native GnRH. Several long-acting depot formulations of leuprolide acetate (ranging from 1-month to 6-month intramuscular injections) have been ...
Kristof Chwalisz, M.D., Ph.D.
doaj +1 more source
Aвтоимун тироидит по долга употреба на агонист на гонадотропин- ослободувачки хормон како третман за предвремен централен пубертет – приказ на случај [PDF]
, 2020 There is a small number of studies that have reported abnormalities in endocrine function after a long-term gonadotropin-releasing hormone agonist (GnRHa) treatment in girls. This treatment is considered as safe and effective by most authors.
Krstevska-Konstantinova, Marina +3 more
core +2 more sources
Frontiers in Pediatrics, 2023 IntroductionCentral precocious puberty (CPP) results from premature activation of hypothalamic-pituitary-gonadal axis, with the consequent increase of gonadotropin-releasing hormone (GnRH); GnRH agonists (GnRHa) represent the gold-standard therapy in ...
M. Valenzise +13 more
doaj +1 more source
Haematologica, 2020 Treatment of acute leukemia with intensive chemotherapy leads to an increased risk of myelosuppression. Luteinizing hormone (LH) blockade improves hematopoietic recovery in mice after radiation or chemotherapy, through protection of the hematopoietic ...
Iman Abou Dalle +11 more
doaj +1 more source
Leuprolide Acetate Treatment for Ovarian Cysts in Breast Cancer Patients Under Tamoxifen Therapy
Gynecology Obstetrics & Reproductive Medicine, 2022 OBJECTIVE: The aim of this study is to evaluate the outcomes of gonadotropin-releasing hormone agonist treatment for ovarian cysts, which are developed during tamoxifen use due to breast cancer.
Şafak Yılmaz Baran +4 more
doaj +1 more source